Mesoblast Limited (NASDAQ: MESO, ASX: MSB) reported US$36 million in net revenue from its flagship cellular medicine Ryoncil for the fourth fiscal quarter ended June 30, 2026. This quarterly performance contributed to a first full-year post-FDA approval net revenue of US$115 million for the product, with US$66.5 million generated in the second half alone. The strong commercial uptake positions the therapy for expanded use in adult patients with steroid-refractory acute graft versus host disease (SR-aGvHD), a market segment three times larger than the current pediatric indication.

The filing, submitted as an Appendix 4C activity report, details the company’s financial and operational progress. Mesoblast’s net operating cash spend for the full year was US$43.8 million, including US$13.4 million in the second half. To strengthen its balance sheet, the company drew down US$50 million from an existing five-year facility to extinguish all maturing debt obligations, leaving it with US$103 million in cash as of June 30, 2026.

Financial Highlights

Operational Progress and Pipeline

Mesoblast is advancing its strategy to extend the FDA-approved label for Ryoncil beyond pediatric patients to adults with SR-aGvHD. The registration trial for this label extension has commenced, with up to 40 sites across the U.S. expected to activate this year. These sites represent approximately 60% of the ~8,500 annual U.S. allogeneic adult bone marrow transplant population.

Additionally, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for a registrational trial evaluating Ryoncil in ambulatory children aged 5-9 years with Duchenne muscular dystrophy (DMD), affecting approximately 15,000 children in the U.S.

In its pipeline for rexlemestrocel-L, Mesoblast achieved its target of treating at least 300 patients in the MSB-DR004 pivotal Phase 3 trial for chronic low back pain associated with degenerative disc disease. Patients will be followed through the twelve-month primary endpoint to assess pain reduction. The company also received a Biologics License Application (BLA) filing number from the FDA for rexlemestrocel-L in preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients with left ventricular assist devices.

Corporate Governance and Compensation

As required by ASX listing rule 4.7, Mesoblast disclosed director remuneration in Item 6 of its Appendix 4C cash flow report. Fees to Non-Executive Directors totaled US$185,862, while consulting payments to Non-Executive Directors were US$100,000. Salary payments to full-time Executive Directors amounted to US$400,206 for the quarter.

What the Numbers Show

The revenue trajectory indicates accelerating adoption of Ryoncil, with second-half revenues (US$66.5 million) significantly outpacing the first half. The decision to extinguish maturing debt using existing credit facilities rather than raising new equity preserves shareholder value and extends the company’s runway. With US$103 million in cash and a clear path to expanding Ryoncil into larger adult markets, Mesoblast is positioning itself for potential FDA approvals that could drive further commercial scale.

Mesoblast Limited has achieved its target of treating at least 300 patients in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection seen in the earlier MSB-DR003 trial. This milestone ensures the study is well powered for success, with commercial manufacturing proceeding in parallel to facilitate a potential Biologics License Application (BLA) filing.

Silviu Itescu, Chief Executive of Mesoblast, stated that completing the patient enrollment target allows the company to proceed toward a results readout and subsequent approval filing as soon as possible. The primary endpoint is powered to show a significant difference in pain reduction at 12 months between rexlemestrocel-L and sham controls. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids.

The indication represents a significant commercial opportunity, with a prevalence of over 7 million people in the U.S. alone. Mesoblast projects potential peak year revenue of >US$10 billion with single-digit market penetration. The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA), providing eligibility for priority review upon BLA submission.

Trial Details and Design

The MSB-DR004 trial is a 300-patient randomized, placebo-controlled confirmatory Phase 3 study. It is actively enrolling patients with chronic low back pain due to inflammatory degenerative disc disease of less than five years duration at multiple sites across the U.S. The FDA has agreed to the trial design and the 12-month primary endpoint of pain reduction as an approvable indication.

A particular focus of the trial is on patients currently using opioids, as discogenic back pain accounts for approximately 50% of prescription opioid usage in the U.S. Significant pain reduction and opioid cessation were observed in Mesoblast’s first Phase 3 trial.

Key Milestones and Designations